A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone

Zeynep Cakir, Ayhan Saritas, Mucahit Emet, Sahin Aslan, Ayhan Akoz, Fuat Gundogdu
Departments of Emergency Medicine and Cardiology, Atatürk University Faculty of Medicine, Erzurum, Turkey

Abstract

Aim: To study brain natriuretic peptide (BNP) levels in three subgroups: patients having stroke with hypertension (HT), those having stroke without HT, and those with HT alone. We also tried to identify whether BNP levels predict the length of stay in hospital and mortality.

Materials and Methods: The groups were formed by patients who had been admitted to the emergency department in the first 4–12 h after the onset of symptoms. There were 30 stroke patients with a history of HT (group I), 30 stroke patients without a history of HT (group II), and 20 HT patients without stroke (group III). Patients with congestive heart failure, chronic cor pulmonale, severe valvular heart disease, chronic renal failure, liver insufficiency, diabetes mellitus, atrial fibrillation, and those with a history of stroke were excluded from the study since these diseases can affect the plasma BNP levels. Results: The demographic characteristics, except the age distribution, were similar among the groups. The mean BNP levels in the three groups were 168.8 ± 223.9 pg/ml, 85.0 ± 75.1 pg/ml, and 84.8 ± 178.3 pg/ml, respectively. The differences between the groups were statistically significant. Conclusion: The mean BNP levels were affected by HT and/or stroke. The simultaneous presence of HT and stroke results in a more significant increase BNP than the presence of either stroke or HT alone. When diseases that can affect the plasma BNP levels are excluded, the BNP levels in stroke patients without a history of HT are similar to the levels seen in patients with only HT.

Key Words
Brain natriuretic peptide, echocardiography, hypertension, stroke

Introduction

Stroke has been defined as a sudden onset of focal and global neurological symptoms due to diseases of cerebral blood vessels leading to hemorrhage and ischemia in the brain. Besides being a serious health problem because of the high mortality and morbidity, stroke has social and economic implications. For this reason, determination of the etiology of the disease and, especially, eradication of the risk factors is of great importance. Comprehensive multicenter, studies have shown that there is a positive and continuous relationship between the incidence of stroke and both systolic and diastolic blood pressures.

Brain natriuretic peptide (BNP), which has diuretic, natriuretic, and vasodilatory effects, is a peptide-structured neurohormone released mainly from the cardiac ventricle in response to volume and pressure loads. Recent studies have shown that the plasma BNP level has an important place in the diagnosis and treatment of cardiovascular diseases, especially cardiac failure and acute coronary syndrome. It is thought that BNP, produced as a result of cardiovascular changes following ischemic stroke, has an important role in the hemodynamics of these patients. The BNP levels can be measured at the bedside, making it easy to follow up the patients in the emergency department (ED).

Several cardiac abnormalities such as myocardial necrosis and arrhythmia can develop in acute stroke patients. These cardiac changes may cause increased BNP production by the heart and, therefore, to study the relationship between BNP levels and stroke correctly, it is better to exclude those stroke patients who also have cardiac pathologies.

There have not been a sufficient number of studies in the literature comparing the plasma BNP levels between stroke patients with a history of hypertension (HT), stroke patients without a history of HT, and hypertensive patients without stroke. We therefore aimed to study BNP levels in these three subgroups: patients having stroke with hypertension, those having stroke without hypertension, and those with hypertension alone. We also tried to identify whether BNP levels could be used to predict the length of stay in hospital and mortality.

Materials and Methods

This prospective study was performed in the emergency department of the Faculty of Medicine, Atatürk University, between November 2006 and November 2007. The subjects
were patients who had been admitted to the ED in the first 4–12 h after the onset of symptoms. The three groups were as follows: 30 stroke patients with history of HT (group I), 30 stroke patients without a history of HT (group II), and 20 HT patients without stroke (group III). The body mass index (BMI) of all the patients were calculated and the neurological deficits were assessed according to the Glasgow coma scale (GCS) and National Institutes of Health Stroke Scale (NIHSS) (0–42 score). On the basis of the mean NIHSS scores, stroke patients were grouped into three according to the expected prognosis (0–6 points: good prognosis, 7–15 points: intermediate, and 16–42 points: bad prognosis). On the basis of the history and initial laboratory and imaging studies, patients with congestive heart failure, chronic cor pulmonary, severe valvular heart disease, chronic renal failure, liver insufficiency, diabetes mellitus, atrial fibrillation (AF), and those with a history of stroke were excluded from the study (a total of 93 patients) since these diseases can affect the plasma BNP levels.

The data were analyzed using the SPSS 15 software. Data were expressed as frequencies, percentages, and means (with standard deviations). The Kruskal-Wallis test, the Mann-Whitney test, the one-way ANOVA, and the t test were used for comparison of means of continuous variables. The Chi-square test was used for analysis of the categorical variables. Differences were accepted as significant when the P-value was < 0.05.

Results

A total of 80 patients were included in the study. The mean age was 60.7 ± 14.1 years (range 28–85); 47 (58.8%) of the subjects were female. BCT revealed hemorrhage in 37 patients (46.3%). The clinical features and demographic data, such as sex, age, BNP levels, and echocardiographic parameters, are presented in Table 1.

The mean BNP level of all patients included in the study was 116.8 ± 173.5 pg/ml. The mean BNP levels in groups I, II, and III were 168.8 ± 223.9 pg/ml, 85.0 ± 75.1 pg/ml, and 84.8 ± 178.3 pg/ml, respectively. The differences between the groups were significant. The mean serum BNP levels in males and females were 121.03 ± 212.11 pg/ml and 113.92 ± 143.79 pg/ml, respectively; this difference was not statistically significant (P = 0.8). There was a significant positive correlation between the mean BNP levels and the ages of the patients (r = 0.53; P<0.001). Echocardiographic parameters of all patients were in the normal range and there were no significant differences between the groups. There was no correlation between the mean BNP levels and the left ventricular ejection fraction (LVEF) (r = −0.2; P = 0.05), left ventricular end-diastolic diameter (LVEDD) (r = 0.2; P = 0.1), and left ventricular end-diastolic diameter (LVESD) (r = 0.1; P = 0.3). There was a positive correlation between mean arterial pressure (MAP) and mean BNP levels (r = 0.33; P<0.05) [Figure 1]. The mean score of the patients on the GCS was 13.6 ± 2.7. A significant negative correlation was found between the GCS score and the mean BNP levels (r = −0.3; P<0.05) [Figure 2].

Table 1: Demographic and clinical characteristics in the three patient groups

| Patient groups                       | Group I n (%) or Mean ± SD | Group II n (%) or Mean ± SD | Group III n (%) or Mean ± SD | P         |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------|
| Age (year)                           | 68.0 ± 11.2                 | 57.2 ± 15.7                 | 55.0 ± 11.2                 | <0.05     |
| Gender                               |                             |                             |                            |           |
| Female                               | 20 (42.6)                   | 16 (34.0)                   | 11 (23.4)                   | NS        |
| Male                                 | 10 (30.3)                   | 14 (42.4)                   | 9 (27.3)                    |           |
| Systolic blood pressure (mm Hg)      | 182.1 ± 30.9                | 150.8 ± 26.5                | 198.5 ± 2.2                 | <0.001    |
| Diastolic blood pressure (mm Hg)     | 106.5 ± 18.0                | 91.6 ± 14.6                 | 115.5 ± 14.7                | <0.001    |
| Mean arterial pressure (mm Hg)       | 131.6 ± 19.9                | 111.3 ± 17.0                | 143.2 ± 15.3                | <0.001    |
| Blood urea nitrogen (BUN)            | 17.2 ± 4.5                  | 16.7 ± 7.6                  | 16.4 ± 5.3                  | NS        |
| Creatinine                           | 0.9 ± 0.4                   | 0.8 ± 0.2                   | 0.9 ± 0.2                   | NS        |
| Brain natriuretic peptide (pg/ml)    | 168.8 ± 223.9               | 85.0 ± 75.1                 | 84.8 ± 178.3                | <0.05     |
| Left ventricular end-diastolic diameter (mm) | 42.4 ± 6.1                  | 42.3 ± 5.6                  | 41.2 ± 5.1                  | NS        |
| Left ventricular end-systolic diameter (mm) | 29.9 ± 5.6                  | 30.2 ± 6.2                  | 27.5 ± 4.1                  | NS        |
| Left ventricular ejection fraction (%) | 61.4 ± 6.4                  | 62.7 ± 7.8                  | 64.4 ± 4.4                  | NS        |
| Body mass index                      | 26.5 ± 3.9                  | 26.0 ± 3.5                  | 28.3 ± 3.6                  | NS        |
| Glasgow coma score (3-15 points)     | 12.9 ± 2.8                  | 13.3 ± 3.1                  | 15.0 ± 0.0                  | <0.001    |
The Spearman correlation analyses for the mean BNP levels and clinical parameters of the three groups are displayed in Table 2.

The mean duration of hypertension was 7.5 ± 6.4 years (range 1–25 years). No correlation was found between the duration of hypertension and the mean BNP levels (P = 0.5). The antihypertensive drugs received by the patients are listed in Table 3. Eight patients were not using any antihypertensive agent. No information was available about the drugs used in 12 patients.

Thirty-seven of the stroke patients (61.7%) had hemorrhage on BCT. There is no relationship between plasma BNP levels and hemorrhage or infarct (P = 0.4). We studied how mean BNP levels predicted the progress of patients; the mean BNP level of stroke patients who were discharged from hospital was found to be 111.0 ± 146.6 pg/ml and the mean BNP level of patients who died was 172.2 ± 226.4 pg/ml; the difference was not statistically significant (P = 0.1). Furthermore, no significant correlation was found between the length of stay in hospital and the mean BNP levels of stroke patients (r = 0.1; P = 0.5). The mean score of stroke patients on the National Institutes of Health Stroke Scale (NIHSS) (in which the score ranges from 0–42) was found to be 10.6 ± 6.3. There was no significant correlation between the mean NIHSS scores and the mean BNP levels (r = 0.2; P = 0.09). There was no significant difference according to the BNP levels among the three NIHSS groups (0–6 points: good prognosis, 7–15 points: intermediate, and 16–42 points: bad prognosis) (P = 0.2).

**Discussion**

BNP, which is a member of the natriuretic peptide family, was first isolated from the pig brain in the 1980s.\(^ {15,16}\) Fluid-
Electrolyte equilibrium is maintained by the action of BNP on the central and peripheral nervous system. BNP has diuretic, natriuretic, and vasodilator effects. Diuresis and natriuresis are achieved by BNP's effect on renal hemodynamics or by a direct effect on renal tubules. High plasma BNP concentrations are seen not only in patients with chronic heart failure or acute myocardial infarction but also in patients with essential HT and arrhythmias such as atrial fibrillation. The serum level of BNP, which is a neurohormone that plays a key role in volume hemostasis, is a sensitive sign of ventricular dysfunction in asymptomatic and asymptomatic patients and is closely related with the severity of dysfunction. Excluding patients with left ventricular dysfunction and other diseases that can affect the mean BNP levels allowed us to better understand the changes in the mean BNP levels in patients with stroke and hypertension.

In the studies of Kjær et al. and Wei et al., a negative correlation was found between LVEF and mean BNP levels. In our study, there was a weak negative correlation between LVEF and plasma BNP levels. Decrease in the LVEF increases the tension in the ventricular wall and the mean BNP levels increase in parallel to this increase in tension. Mayer et al. reported a positive correlation between LVESD, LVEDD, and plasma BNP levels in a study evaluating the BNP level in patients with heart failure and coexisting mitral regurgitation. In our study, no significant correlation was found between LVEDD, LVESD, and plasma BNP levels. This may be because we included patients with normal left ventricular functions to achieve a correct evaluation of stroke and mean BNP levels.

The mean BNP levels were found to be 26.2 ± 1.8 pg/ml in patients between 55 and 64 years of age, 31.0 ± 2.4 pg/ml in patients between 65 and 74 years of age, and 63.7 ± 6.0 pg/ml in patients over 75 years of age. The BNP levels of female patients with heart failure were higher than that of males of the same age-group. In their study, Suzuki et al. found that there was a positive correlation between plasma BNP levels and age, regardless of whether the patient had hypertension or normotension. We too found a significant positive correlation between age and plasma BNP levels in all patients. According to the literature reports there is a decrease in left ventricular compliance with age and our finding of the increase in plasma BNP levels with age is consistent with this.

Blood pressure is frequently increased in the acute phase of stroke. Deterioration in cerebral blood flow regulation, increased stress due to hospitalization, increased sympathetic activation, or increased intracranial pressure have all been blamed for this effect. Although the blood pressure was found to be high in the acute phase of stroke, HT was found only in one-third of the patients in one study. In the study by Nakagawa et al., it was found that although patients with intracranial hemorrhage (ICH) had higher MAP levels than patients with ischemic stroke, the serum BNP levels were higher in patients with ICH than in those with ischemic stroke. In the same study, it was shown that there was a weak positive correlation between the MAP levels and the BNP levels at the beginning of the ischemic stroke. In a study performed by Brosnan et al. in order to explore the relationship between MAP and BNP, it was found that in hypertensive patients the BNP levels increased with increase in the blood pressure. However, in our study, no significant correlation was found between plasma BNP levels and MAP in any of the study groups. Nevertheless, when all the patients were evaluated carefully, it could be seen that there was a significant positive correlation between plasma BNP levels and MAP. On the basis of these results, it can be said that increase in cardiac wall tension and intracardiac pressure and volume due to increase in the MAP leads to a proportionate increase in plasma BNP level.

In the studies of Estrada et al. and Eguchi et al., it was found that BNP levels increased in the acute phase of stroke and that there was a positive correlation between blood pressure levels and BNP levels. In the another study, on patients with subarachnoid hemorrhage, it was estimated that plasma BNP levels in patients with HT were higher than that in patients without HT. In our study we found that plasma BNP levels in stroke patients with HT was higher than in stroke patients who did not have HT. This shows that HT increases the plasma BNP levels irrespective of whether stroke is present or not.

In the study of Makikallio et al. it was estimated that high plasma BNP levels in the acute phase of stroke were related with increased mortality and high plasma BNP levels were better prognostic indicators of mortality after stroke than the other risk factors. Furthermore, it has been reported that patients with high plasma BNP levels have a four-fold higher mortality. However, no significant correlation was noted between GCS score and BNP levels. In the study of Makikallio et al. it was shown that measurement of BNP in stroke patients could be used in risk classification and estimation of mortality risk. In one of the studies of Sviri et al. it was found that there was a relationship between plasma BNP levels and the development of cerebral ischemia and neurological deficits. A strong correlation was found between GCS score and the BNP levels of the patients. The NIHSS score, which is used in an ideal neurological evaluation, ranges between 0–42 points and correlates with the size of the infarct. The NIHSS score is the most important determining factor for estimation of the severity of stroke initially and for assessing the mortality risk. An NIHSS score of ≥ 16 is associated with higher mortality and bad functional capacity. On the other hand, an NIHSS score of ≤ 6 is related with a good functional capacity. In their study, Tomita et al. found that there is a positive correlation between the NIHSS score and BNP levels in stroke patients. However, Giannakoulas et al. did not find a correlation between NIHSS and BNP levels. In our study, we did not find a significant correlation between NIHSS and plasma BNP levels. Moreover, although the BNP levels of the patients with NIHSS scores of ≥ 16 was greater than the levels seen in the other groups, the difference was not significant. There was a significant negative correlation between GCS score and plasma BNP levels in our study. For this reason, we thought that plasma BNP levels can be of use at the time of admission for correctly estimating the severity of the stroke, the functional capacity, and the clinical progress of stroke patients.

There are some limitations in our study. As short-term prognosis depends on many factors other than the BNP level, additional studies and more detailed statistical analyses are needed to find out the relationship of BNP with the prognosis. The size of the hemorrhage and the infarct area were not evaluated in our study. Also, the age distribution was not
homogenous among the groups. All these factors may affect our conclusions. However, exclusion of systemic diseases that may have affected the BNP levels has rendered our study valuable. The mean BNP levels in our study subjects were affected only by HT and stroke. When both HT and stroke coexist there is a more significant BNP increase than when either stroke or HT alone are present. When the diseases that can affect the plasma BNP levels are excluded, plasma BNP levels in stroke patients without a history of HT are similar to the levels seen in patients with only HT.

Acknowledgments

The authors are grateful to Prof. Dr Fatih Akcay for his services.

References

1. Sacco RL, Tatemichi TK, Brust JCM. Vascular diseases. In: Rowland LP, editor. Merritt’s Textbook of Neurology. 9th ed. New York: A Waverly Company; 1995. p. 227-55.

2. Oğul E. Beyin Damarı Hastalıkları. Klinik Nöroloji; 2002. p. 1.

3. MacMahon S, Petro R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease: Part I: Prolonged differences in blood pressure: Prospective observational studies corrected for regression dilution bias. Lancet 1990;335:765-74.

4. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in Eastern Asia. Lancet 1998;352:1801-7.

5. Duygu H, Türk U, Zoghi M, Nalbantgil S. Plazma B-tipi natriüretik peptid düzeylerinin kardiyovasküler hastalıklardaki yeri ve önemi. Anadolu Kardiyoloji Dergisi 2005;5:305-11.

6. Nakagawa K, Yamaguchi T, Seida M, Yamada S, Imae S, Tanaka Y, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005;19:157-64.

7. Safley DM, McCullough PA. The emerging role of brain natriuretic peptide in the management of acute and chronic heart failure in outpatients. Heart Fail Monit 2003;4:13-20.

8. Oppenheimer SM, Lima J. Neurology and the heart. J Neurol Neurosurg Psychiatry 1998;64:289-97.

9. Myers MG, Norris JW, Hachinski VC, Weingert ME, Sole MJ. Cardiac sequelae of acute stroke. Stroke 1982;13:838-42.

10. Brosnan MJ, Clark JS, Jeffs B, Negin CD, Van Vooren P, Arribas et al. Genes encoding atrial and brain natriuretic peptides as candidates for sensitivity to brain ischemia in stroke-prone hypertensive rats. Hypertension 1999;33:290-7.

11. Bulut M, Aydin ŞA. İmne. In: Satar S, Karcioğlu Ö, editors. Kardiyak Aciller. 1st ed. Adana: Nobel Kitabevi; 2008. p. 457-80.

12. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Breathing not properly multination study investigators: Rapid measurement of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.

13. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinationl Study. Circulation 2002;106:416-22.

14. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompenated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386-91.

15. Cheung BM, Kumana CR. Natriuretic peptides-relevance in cardiac disease. JAMA 1998;280:1982-4.

16. Stein BC, Levine RI. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23.

17. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.

18. Bonow RO. New insight to the cardiac natriuretic peptides. Circulation 1996;93:1946-50.

19. Rossi A, Enríquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-62.

20. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321.

21. Meune C, Fulla Y, Martins E, Bergmann JF, Devaux JY. B-type natriuretic peptide for the diagnostic and prognostic assessment in cardiology: Its interest and perspectives of application. Presse Med 2003;32:181-5.

22. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003;14:13-9.

23. Wei T, Zeng C, Chen L, Zhao R, Lu G, Lu C, et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 2005;7:75-9.

24. Kjaer A, Hildebrandt P, Appel J, Petersen CL. Neurohormones as markers of right-left sided cardiac dimensions and function in patients with untreated chronic heart failure. Int J Cardiol 2005;99:301-6.

25. Mayer SA, De Lemos JA, Murphy SA, Brooks S, Roberts BJ, Grayburn PA. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. Am J Cardiol 2004;93:1002-6.

26. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002;25:669-76.

27. Chalmers J, Macmahon S, Anderson C, et al. Clinician’s manual on blood pressure and stroke prevention. 2nd ed. 2000. p. 45.

28. Estrada V, Teilez MJ, Moya J, Fernandez-Durango R, Egido J, Cruz AF. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute isstroke. Am J Hypertens 1994;7:1085-9.

29. Eguchi K, Kario K, Shimada K, Mori T, Nii T, Ibaragi K. Cirkadien variation of blood pressure and neurohumoral factors during the acute phase of stroke. Clin Exp Hypertens 2002:24:109-14.

30. Tung PP, Olmsted E, Kopolnik A, Banki NM, Drew BJ, Ko N, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachindose hemorrhage. Stroke 2005;36:1567-9.

31. Makkikalio AM, Makkialio TH, Korpelainen JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, et al. Natriuretic peptides and mortality after stroke. Stroke 2005;36:1016-20.

32. Sviri GE, Shik V, Baz M, Soustiel JF. Role of brain natriuretic peptide in cerebral vasospasms. Acta Neurochir 2003;145:551-60.

33. Tomita H, Metoki N, Saitoh G, Ashitate T, Echizen T, Katoh C, et al. Elevated plasma brain natriuretic peptide levels independent of heart disease in acute ischemic stroke: Correlation with stroke severity. Hypertens Res 2008;31:1695-702.

34. Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 2005;56:723-30.